This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Should Vanguard SmallCap Growth ETF (VBK) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VBK
Techne (TECH) Lags Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Techne (TECH) delivered earnings and revenue surprises of -3.78% and 4.34%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
EXEL or TECH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
EXEL vs. TECH: Which Stock Is the Better Value Option?
EXEL vs. TECH: Which Stock Is the Better Value Option?
by Zacks Equity Research
EXEL vs. TECH: Which Stock Is the Better Value Option?
Should Vanguard SmallCap Growth ETF (VBK) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VBK
Seagen's (SGEN) Cancer Drugs Aid Growth, Stiff Rivalry a Woe
by Zacks Equity Research
Seagen (SGEN) focuses on improving sales of its marketed drugs approved for different types of cancer indications. Stiff competition in the market remains a woe.
Axsome (AXSM) Q2 Loss Narrower Than Expected, Revenues Miss
by Zacks Equity Research
Axsome (AXSM) reports narrower-than-expected loss for the second quarter of 2022. The company records its first sales of the sleep drug, Sunosi, which it acquired from Jazz.
Acadia's (ACAD) Q2 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Acadia (ACAD) reports a narrower-than-expected loss for the second quarter of 2022 while revenues surpass estimates. Tightens guidance for Nuplazid.
Global Blood (GBT) to be Acquired by Pfizer, Misses on Earnings
by Zacks Equity Research
Global Blood (GBT) is set to be acquired by Pfizer for around $5.4 billion. The company missed estimates for earnings while beating the same for revenues in the second quarter of 2022.
3 Reasons Why Techne (TECH) Is a Great Growth Stock
by Zacks Equity Research
Techne (TECH) possesses solid growth attributes, which could help it handily outperform the market.
MRNA vs. TECH: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
MRNA vs. TECH: Which Stock Is the Better Value Option?
Wall Street Analysts Think Techne (TECH) Could Surge 30%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 29.7% in Techne (TECH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Techne (TECH) Lags Q4 Earnings Estimates
by Zacks Equity Research
Techne (TECH) delivered earnings and revenue surprises of -0.49% and 0.28%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Apellis Pharmaceuticals, Inc. (APLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Techne (TECH) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
INCY vs. TECH: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
INCY vs. TECH: Which Stock Is the Better Value Option?
Should Vanguard SmallCap Growth ETF (VBK) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VBK
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Does Techne (TECH) Have the Potential to Rally 39% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 39% in Techne (TECH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PBE
Techne (TECH) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Techne (TECH) delivered earnings and revenue surprises of 7% and 2.47%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
HZNP or TECH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HZNP vs. TECH: Which Stock Is the Better Value Option?
Should Vanguard SmallCap Growth ETF (VBK) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VBK
Gilead Sciences (GILD) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Gilead (GILD) delivered earnings and revenue surprises of 19.77% and 6.46%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE